2nd Quarter - Report

TCH GROUP, LLC for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA

Firm
Client
Income
$40,000
Expenses
—

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Medicare Part D issues. H.R. 928 Medicare Prescription Drug Savings and Choice Act of 2013: Provisions related to patent issues. H.R. 2190 Medicare Drug Savings Act: Part D Issues S. 117 Medicare Prescription Drug Price Negotiation Act of 2013S. 351 Protecting Seniors Access to Medicare Act of 2013 S. 408 Medicare Prescription Drug Savings and Choice Act of 2013

LobbyistCovered position, as disclosed
JOHN HOLSCLAW —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 928 (113th), S. 117 (113th), H.R. 2190 (113th), S. 408 (113th)

Budget/Appropriations BUD

S.CON.RES.8, An original resolution setting forth the congressional budget for the United States Government for fiscal year 2014, revising the appropriate budgetary levels for fiscal year 2013, and setting forth the appropriate budgetary levels for fiscal years 2015 through 2023.

LobbyistCovered position, as disclosed
JOHN HOLSCLAW —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: S.Con.Res. 8 (113th)

Health Issues HCR

General heath care coverage and reimbursement; implementation issues regarding H.R. 3590, the Patient Protection and Affordable Care Act; and the Food and Drug Administration legislative regulatory issues. Drug Safety Issues. Drug shortage. Issues related to Pharmaceutical Importation. Issues related to generic drugs.

LobbyistCovered position, as disclosed
JOHN HOLSCLAW —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 3590 (113th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.